Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$1.18
-0.02 (-1.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-2.4M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-78.4%
↓Gross Margin
38.2%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+2.8%
FCF CAGR
—
FCF margin
-1.2%
FCF / Net income
0.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.3M · net income $-3.5M · FCF $-168000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $14.3M | $14.3M | $12.7M | $13.3M | $12.6M | $18.6M | $17.9M | $19.0M | $16.7M | $12.8M | $9.4M | $13.9M | $13.7M | $15.5M | $12.7M | $9.8M |
| Net Income | $-3.5M | $-3.5M | $-4.8M | $-5.2M | $-5.1M | $-4.0M | $-3.3M | $-11.8M | $-14.3M | $9.3M | $-10.2M | $-8.2M | $3.7M | $-5.4M | $-7.3M | $-7.9M |
| EBITDA | $-3.6M | $-3.6M | $-4.5M | $-4.4M | $-5.7M | $-3.2M | $-7.1M | $-10.8M | $-13.7M | $-12.7M | $-14.5M | $-6.4M | $-5.8M | $-3.1M | $-6.1M | $-7.1M |
| EPS | -2.79 | -2.79 | -10.63 | -30.40 | -38.40 | — | — | — | — | — | — | -765.00 | 486.00 | -1170.00 | — | — |
| Gross Margin | 38.2% | 38.2% | 37.3% | 33.7% | 31.6% | 35.2% | 45.3% | 46.8% | 43.9% | 44.2% | 28.3% | 52.6% | 61.4% | 69.5% | 68.4% | 63.0% |
| Operating Margin | -26.0% | -26.0% | -36.9% | -34.4% | -46.6% | -18.5% | -41.2% | -59.3% | -85.2% | -101.2% | -157.0% | -48.1% | -44.3% | -21.8% | -50.7% | -76.9% |
| Net Margin | -24.2% | -24.2% | -38.0% | -38.8% | -40.3% | -21.2% | -18.5% | -62.2% | -86.0% | 72.3% | -108.5% | -59.2% | 27.3% | -35.1% | -57.5% | -81.5% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.07 | 0.07 | 0.10 | 0.11 | 0.16 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | -2.10 | 0.96 |
| Current Ratio | 2.88 | 2.88 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-168000.00 | $-168000.00 | $-2.4M | $-6.4M | $-4.4M | $-3.6M | $-4.8M | $-11.8M | — | — | — | — | — | $893000.00 | $-4.4M | $-4.6M |
| Returns | ||||||||||||||||
| ROE | -78.4% | -78.4% | -78.8% | -64.6% | -58.5% | -73.7% | -58.8% | -151.8% | -93.5% | 43.3% | -100.2% | -68.1% | 31.0% | -133.1% | 844.4% | -467.3% |
| Valuation | ||||||||||||||||
| P/B | 0.33 | 0.33 | 0.22 | 0.40 | 1.12 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 12.2% | 12.2% | -4.0% | 5.1% | — | 3.9% | -5.5% | 13.9% | 29.9% | 36.9% | -32.4% | 1.4% | -11.5% | 21.2% | 30.7% | — |
| EPS Growth | 73.8% | 73.8% | 65.0% | 20.8% | — | — | — | — | — | — | — | -257.4% | 141.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-65.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-10.63 → -2.79
Residual
-65.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.